Drug Profile
Lacosamide - UCB
Alternative Names: ADD 234037; Erlosamide; Harkoseride; SPM 927; SPM 929; Vimpat; VIMPATÒLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator University of Houston
- Developer Daiichi Sankyo Company; Duke University; UCB
- Class Acetamides; Analgesics; Antiepileptic drugs; Benzene derivatives; Neuroprotectants; Small molecules
- Mechanism of Action CRMP2 protein modulators; Glycine gated NMDA receptor antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Partial epilepsies; Tonic-clonic epilepsy
- Phase III Generalised seizures
- Phase II/III Epilepsy; Neonatal seizures
- Phase II Seizures
- No development reported Essential tremor; Fibromyalgia; Osteoarthritis; Pain; Sleep disorders
- Discontinued Migraine; Neuropathic pain
Most Recent Events
- 30 Mar 2023 UCB completes the phase III VALUE trial in Generalised seizures (Adjunctive treatment, In adolescents, In children, In adults, In the elderly) in USA, Australia, Brazil, South Korea, Israel, Russia, Turkey, Taiwan, Japan, Mexico, Bulgaria, Belgium, China, Czech Republic, France, Germany, Hungary, Italy, Poland, Portugal, Romania, Russia, Slovakia, Spain (PO) (EudraCT2012-001770-29) (NCT02408549)
- 18 May 2021 UCB completes a phase II trial in Epilepsy (Adjunctive therapy, In infants, In children and Adolescents) in the Belgium, China, France, Germany, Hungary, Italy, Japan, Mexico, Poland, Ukraine and USA (NCT00938912)
- 29 Dec 2020 UCB Biopharma initiates enrolment in the long term phase III extention trial for Epilepsy in Hungary and Georgia (NCT04627285)